MCID: MLG074
MIFTS: 51

Malignant Mesenchymoma

Categories: Rare diseases, Cancer diseases, Nephrological diseases

Aliases & Classifications for Malignant Mesenchymoma

MalaCards integrated aliases for Malignant Mesenchymoma:

Name: Malignant Mesenchymoma 12 49 14
Malignant Mesenchymal Tumor 49 41 69
Rat Malignant Renal Mesenchymal Tumor 69
Mesenchymoma, Malignant 12
Sarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5758
MeSH 41 C535700
NCIt 46 C4268
SNOMED-CT 64 89623007

Summaries for Malignant Mesenchymoma

MalaCards based summary : Malignant Mesenchymoma, also known as malignant mesenchymal tumor, is related to mesenchymoma and gallbladder sarcoma. An important gene associated with Malignant Mesenchymoma is MB (Myoglobin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Carboplatin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and heart, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Mesenchymoma

Diseases in the Mesenchymoma family:

Benign Mesenchymoma Malignant Mesenchymoma
Adult Malignant Mesenchymoma

Diseases related to Malignant Mesenchymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Related Disease Score Top Affiliating Genes
1 mesenchymoma 31.8 DES MB MDM2 MYOD1
2 gallbladder sarcoma 31.7 DES KIT MYOD1 MYOG
3 cystic nephroma 30.0 DES KIT WT1
4 conventional central osteosarcoma 30.0 EWSR1 MDM2
5 liposarcoma 29.8 CDK4 DES EWSR1 MB MDM2 TP53
6 suppressor of tumorigenicity 3 29.8 CDKN1A FHIT TP53
7 fibrosarcoma 29.7 CDKN1A DES ETV6 NTRK3
8 glioblastoma 29.4 CDK4 CDKN1A MDM2 TP53
9 sarcoma 29.4 EWSR1 KIT MDM2 SSX2B TP53
10 rhabdomyosarcoma 28.6 CDK4 DES EWSR1 MB MDM2 MYOD1
11 leiomyosarcoma 28.4 CDK4 DES KIT MB MDM2 MYOG
12 childhood malignant mesenchymoma 12.1
13 adult malignant mesenchymoma 12.1
14 giant cell myocarditis 10.6 DES MB
15 prostate embryonal rhabdomyosarcoma 10.6 KIT MYOD1
16 ovarian fibrothecoma 10.6 DES KIT
17 malignant triton tumor 10.5 DES MB MYOD1
18 spindle cell rhabdomyosarcoma 10.5 DES MB MYOD1
19 cervical polyp 10.5 DES MYOD1
20 adult mesoblastic nephroma 10.5 ETV6 NTRK3
21 spindle cell lipoma 10.5 CDK4 DES MDM2
22 spindle cell sarcoma 10.5 DES MDM2 NTRK3
23 mixed liposarcoma 10.5 CDK4 MB MDM2
24 alveolar soft part sarcoma 10.4 DES MB MYOD1
25 ischemic fasciitis 10.4 CDK4 DES MDM2
26 extraosseous osteosarcoma 10.4 CDK4 GALNT3 MDM2
27 lipomatosis, multiple 10.4 CDK4 DES MDM2
28 cutaneous ganglioneuroma 10.4 KIT NCAM1
29 congenital fibrosarcoma 10.4 DES ETV6 NTRK3
30 infiltrating angiolipoma 10.4 CDK4 MDM2
31 pediatric fibrosarcoma 10.4 ETV6 NTRK3
32 meninges sarcoma 10.4 MB TP53
33 sclerosing liposarcoma 10.4 MB MDM2 TP53
34 sarcomatoid squamous cell skin carcinoma 10.3 KIT MB TP53
35 mesenchymal cell neoplasm 10.3 EWSR1 KIT MYOD1
36 testicular gonadoblastoma 10.3 KIT WT1
37 myxosarcoma 10.3 MB MDM2 TP53
38 breast secretory carcinoma 10.3 CDK4 ETV6 NTRK3
39 malignant fibroxanthoma 10.3 CDK4 DES MDM2 MYOD1
40 mixed cell type cancer 10.3 KIT MB TP53
41 ring chromosome 7 10.3 CDK4 MDM2 TP53
42 orbital cancer 10.3 EWSR1 MB NCAM1
43 orbit rhabdomyosarcoma 10.3 MB MYOG
44 deep leiomyoma 10.3 CALD1 KIT
45 ewing's family of tumors 10.3 CDK4 EWSR1 KIT
46 periosteal osteogenic sarcoma 10.3 CDK4 MDM2 TP53
47 fallopian tube carcinosarcoma 10.3 NCAM1 WT1
48 grade iii astrocytoma 10.2 CDK4 MDM2 TP53
49 myositis 10.2 MB MYOD1 NCAM1
50 conventional fibrosarcoma 10.2 CALD1 KIT MDM2

Graphical network of the top 20 diseases related to Malignant Mesenchymoma:



Diseases related to Malignant Mesenchymoma

Symptoms & Phenotypes for Malignant Mesenchymoma

GenomeRNAi Phenotypes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 WT1 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.84 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.84 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.84 NTRK3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.84 NTRK3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.84 SSX2B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.84 WT1 KIT NTRK3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 KIT
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.84 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 SSX2B WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.84 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 WT1 KIT NTRK3 SSX2B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.84 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.84 NTRK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 KIT NTRK3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.84 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 WT1 SSX2B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.84 SSX2B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 SSX2B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 KIT NTRK3 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 KIT

MGI Mouse Phenotypes related to Malignant Mesenchymoma:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 MDM2 KIT MYOD1 MB CDK4 DES
2 growth/size/body region MP:0005378 10.36 MDM2 KIT MYOD1 MB GALNT3 CDK4
3 homeostasis/metabolism MP:0005376 10.35 MDM2 KIT MYOD1 MB MYOG GALNT3
4 cellular MP:0005384 10.29 GALNT3 MDM2 KIT MB CDKN1A DES
5 mortality/aging MP:0010768 10.28 MDM2 KIT MYOD1 MB DES CDK4
6 digestive/alimentary MP:0005381 10.24 MDM2 KIT GALNT3 CDK4 ETV6 CDKN1A
7 hematopoietic system MP:0005397 10.24 GALNT3 MDM2 KIT MB CDKN1A CDK4
8 embryo MP:0005380 10.18 MDM2 KIT MB CDKN1A CDK4 ETV6
9 integument MP:0010771 10.16 MDM2 KIT GALNT3 CDK4 ETV6 FHIT
10 muscle MP:0005369 10.11 KIT MYOD1 MB MYOG MDM2 CDK4
11 liver/biliary system MP:0005370 10.03 MDM2 KIT CDK4 CDKN1A WT1 TP53
12 neoplasm MP:0002006 9.97 MDM2 KIT MYOD1 CDK4 ETV6 CDKN1A
13 no phenotypic analysis MP:0003012 9.91 MDM2 KIT MYOD1 ETV6 CDKN1A WT1
14 normal MP:0002873 9.81 MDM2 KIT MYOD1 CDK4 ETV6 TP53
15 renal/urinary system MP:0005367 9.56 MDM2 KIT GALNT3 CDK4 CDKN1A WT1
16 respiratory system MP:0005388 9.28 KIT MYOD1 MB CDKN1A WT1 TP53

Drugs & Therapeutics for Malignant Mesenchymoma

Drugs for Malignant Mesenchymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Morphine Approved, Investigational Phase 3 57-27-2 5288826
8
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
9
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
10
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
11
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
12
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
13
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
14
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
15
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
16
Mesna Approved, Investigational Phase 3 3375-50-6 598
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 3,Phase 2
23 Antimitotic Agents Phase 3,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
25 Antirheumatic Agents Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2
28 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
30 topoisomerase I inhibitors Phase 3,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Adjuvants, Immunologic Phase 3,Phase 1
33
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Gemcitabine Approved Phase 2 95058-81-4 60750
38 Imatinib Mesylate Phase 2,Phase 1 123596
39 Protein Kinase Inhibitors Phase 2,Phase 1
40 Angiogenesis Inhibitors Phase 2,Phase 1
41 Angiogenesis Modulating Agents Phase 2,Phase 1
42 Antimetabolites Phase 2
43 Antimetabolites, Antineoplastic Phase 2
44 Antiviral Agents Phase 2
45 Protective Agents Phase 2
46 razoxane Phase 2
47 Antibodies Phase 1
48 Antibodies, Monoclonal Phase 1
49 Immunoglobulins Phase 1
50 Interleukin-12 Phase 1

Interventional clinical trials:

(show all 32)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
2 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
3 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
9 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
10 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
13 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
14 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
15 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
17 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
18 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
19 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
20 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
23 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
24 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
25 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Active, not recruiting NCT00077285 Phase 2 carboplatin;cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
26 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
27 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
28 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
29 NHS-IL12 for Solid Tumors Recruiting NCT01417546 Phase 1 NHS-IL-12
30 Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX Unknown status NCT00900211
31 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
32 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Malignant Mesenchymoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: malignant mesenchymal tumor

Genetic Tests for Malignant Mesenchymoma

Anatomical Context for Malignant Mesenchymoma

MalaCards organs/tissues related to Malignant Mesenchymoma:

38
Bone, Lung, Heart, Kidney, Liver, Uterus, Prostate

Publications for Malignant Mesenchymoma

Articles related to Malignant Mesenchymoma:

(show top 50) (show all 121)
# Title Authors Year
1
Primary malignant mesenchymoma of bladder: Case report and review of the literature. ( 28796040 )
2017
2
Critical reappraisal of primary osseous composite sarcoma (malignant mesenchymoma) - analysis of four cases and literature review. ( 27102568 )
2016
3
Malignant mesenchymoma with widespread metastasis including bone marrow involvement in a dog. ( 25132008 )
2014
4
Diagnosis and treatment considerations in a case of malignant mesenchymoma in an African fur seal (Arctocephalus pusillus). ( 23805568 )
2013
5
Combined cutaneous sarcoma: pleomorphic liposarcoma and conventional osteosarcoma-the so-called malignant mesenchymoma. ( 23082265 )
2012
6
Malignant mesenchymoma of the heart base in a dog with infiltration of the pericardium and metastasis to the lung. ( 22516086 )
2012
7
Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma. ( 22833086 )
2012
8
Malignant mesenchymoma in the nasal cavity of a bull. ( 21306728 )
2011
9
An intra-abdominal malignant mesenchymoma associated with nonabsorbable sutures in a ferret (Mustela putorius furo). ( 20224105 )
2010
10
Malignant mesenchymoma surrounding the esophageal hiatus. ( 20103193 )
2010
11
Malignant mesenchymoma of the thyroid: case report and literature review. ( 20572598 )
2010
12
Surgical case of giant malignant mesenchymoma in the posterior mediastinum that recurred in the bilateral mediastinum. ( 18781043 )
2008
13
Left atrial malignant mesenchymoma--emergency resection and mitral replacement. ( 17664193 )
2007
14
Uterine malignant mesenchymoma, arising in a leiomyoma, with pulmonary metastases. ( 17257144 )
2007
15
Intermandibular malignant mesenchymoma in a crossbreed dog. ( 16961475 )
2006
16
Malignant mesenchymoma arising from a uterine leiomyoma in the menopause. ( 15581987 )
2004
17
Primary osteochondrorhabdomyosarcoma (malignant mesenchymoma) of the fibula: a rare tumour in an unusual site -- case report and review of the literature. ( 15601312 )
2004
18
Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. ( 15792374 )
2004
19
Malignant mesenchymoma of the orbit: case report and review of the literature. ( 12578773 )
2003
20
Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. ( 12792727 )
2003
21
Malignant mesenchymoma of the pleura. ( 17670075 )
2003
22
Malignant mesenchymoma of the uterus, arising in a leiomyoma. ( 11903599 )
2002
23
Retroperitoneal malignant mesenchymoma: a case of mesenchymal mixed tumor with osteosarcoma, leiomyosarcoma, liposarcoma and fibrosarcoma. ( 12514345 )
2002
24
Radical resection of a malignant mesenchymoma with hypogastric artery transposition. ( 12210036 )
2002
25
Primary malignant mesenchymoma of the heart. ( 11788281 )
2002
26
Malignant mesenchymoma of the lower leg. ( 11684725 )
2001
27
Giant malignant mesenchymoma of the spermatic cord with bidirectional differentiation. ( 11441285 )
2001
28
Retroperitoneal malignant mesenchymoma: imaging findings in five cases. ( 9933683 )
1999
29
Ring chromosomes in a malignant mesenchymoma. ( 10087943 )
1999
30
Malignant mesenchymoma arising in an incisional scar of the abdominal wall. ( 9800981 )
1998
31
Primary left atrial malignant mesenchymoma: a case report. ( 9607271 )
1998
32
Malignant mesenchymoma associated with an unusual vasoinvasive metastasis in a dog. ( 9657162 )
1998
33
Primary osteorhabdomyosarcoma (malignant mesenchymoma) of bone: a case report and review of the literature. ( 9346186 )
1997
34
Radiation-induced malignant mesenchymoma of the chest wall following treatment for breast cancer. ( 9166083 )
1997
35
Malignant mesenchymoma of the spermatic cord with a brief review of the literature. ( 9179703 )
1997
36
Maxillary malignant mesenchymoma and massive fibrous dysplasia. ( 9006514 )
1997
37
Malignant mesenchymoma arising from the prostate in Gardner's syndrome. ( 8776827 )
1996
38
Malignant mesenchymoma. ( 8630953 )
1996
39
Dedifferentiated cystic nephroma with malignant mesenchymoma as the dedifferentiated component. ( 9025898 )
1996
40
Clinical image. Malignant mesenchymoma of the buttock. ( 8933808 )
1996
41
Malignant mesenchymoma of the pleura. ( 8638184 )
1996
42
Malignant mesenchymoma as a primary urinary bladder tumour. ( 7767934 )
1995
43
Malignant mesenchymoma of the thigh. ( 7644947 )
1995
44
Primary malignant mesenchymoma of bone: case report, literature review, and distinction of this entity from mesenchymal and dedifferentiated chondrosarcoma. ( 7644944 )
1995
45
Panuveal malignant mesenchymoma. ( 7668945 )
1995
46
CT findings of retroperitoneal malignant mesenchymoma. ( 8161915 )
1994
47
Malignant mesenchymoma of the prostate: immunohistochemical and ultrastructural observations. ( 7941044 )
1994
48
Malignant mesenchymoma of the spermatic cord. ( 8088727 )
1994
49
A case of retroperitoneal malignant mesenchymoma. ( 7834083 )
1994
50
Retroperitoneal malignant mesenchymoma: a case report. ( 7614386 )
1994

Variations for Malignant Mesenchymoma

Expression for Malignant Mesenchymoma

Search GEO for disease gene expression data for Malignant Mesenchymoma.

Pathways for Malignant Mesenchymoma

Pathways related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 CDK4 CDKN1A FHIT KIT MDM2 TP53
2 12.78 CDK4 CDKN1A KIT MDM2 TP53
3
Show member pathways
12.57 CDK4 CDKN1A MDM2 TP53 UCHL1
4
Show member pathways
12.3 CDK4 CDKN1A MDM2 TP53
5 12.29 CDK4 CDKN1A MDM2 TP53
6 12.21 CDK4 CDKN1A MDM2 TP53
7
Show member pathways
12.16 CDK4 CDKN1A MDM2 TP53
8
Show member pathways
12.09 CDK4 CDKN1A MDM2 NTRK3 TP53
9 12.06 CDK4 CDKN1A MDM2 TP53
10
Show member pathways
12.03 CDK4 CDKN1A MDM2 TP53
11 11.95 CDK4 CDKN1A MDM2 TP53
12 11.8 CDK4 CDKN1A MDM2 TP53
13
Show member pathways
11.77 CDKN1A MDM2 TP53
14 11.74 CDKN1A MDM2 TP53
15 11.71 CDKN1A KIT MYOD1
16 11.7 CDK4 CDKN1A MYOD1
17 11.7 CDK4 CDKN1A FHIT TP53
18 11.66 CDKN1A MDM2 TP53
19 11.61 CDK4 CDKN1A MDM2 TP53
20 11.6 KIT NTRK3 TP53
21 11.51 CDKN1A MDM2 MYOD1
22 11.49 CDK4 CDKN1A MDM2 TP53
23 11.46 CDKN1A TP53 UCHL1
24 11.44 CDKN1A ETV6 EWSR1 MDM2 SSX2B TP53
25 11.34 DES KIT MYOD1 MYOG NCAM1
26 11.3 CDKN1A MYOD1 TP53
27 11.22 CDK4 CDKN1A MDM2 TP53
28 11.18 CDK4 CDKN1A TP53
29 11.16 CDK4 MDM2 TP53
30 11.1 CDK4 CDKN1A MDM2 TP53
31
Show member pathways
10.92 CDKN1A MDM2 TP53
32 10.73 CDKN1A TP53
33
Show member pathways
10.5 CDKN1A TP53

GO Terms for Malignant Mesenchymoma

Cellular components related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 CALD1 CDK4 CDKN1A DES ETV6 FHIT
2 transcription factor complex GO:0005667 9.26 CDK4 MYOD1 MYOG TP53
3 nucleolus GO:0005730 9.17 CDK4 CDKN1A ETV6 EWSR1 MDM2 TP53

Biological processes related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.76 MB MDM2 NTRK3 WT1
2 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.58 CDKN1A MDM2 TP53
3 myotube differentiation GO:0014902 9.49 MYOD1 MYOG
4 replicative senescence GO:0090399 9.48 CDKN1A TP53
5 positive regulation of skeletal muscle fiber development GO:0048743 9.43 MYOD1 MYOG
6 positive regulation of cell cycle GO:0045787 9.43 CDK4 MDM2 TP53
7 muscle cell fate commitment GO:0042693 9.37 MYOD1 MYOG
8 signal transduction by p53 class mediator GO:0072331 9.32 CDKN1A TP53
9 cellular response to actinomycin D GO:0072717 9.16 MDM2 TP53
10 cellular response to gamma radiation GO:0071480 9.13 CDKN1A MDM2 TP53
11 response to hyperoxia GO:0055093 8.8 CDK4 CDKN1A TP53

Molecular functions related to Malignant Mesenchymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.46 ETV6 MYOD1 MYOG TP53
2 p53 binding GO:0002039 9.13 MDM2 NTRK3 TP53
3 ubiquitin protein ligase binding GO:0031625 9.1 CDKN1A FHIT MDM2 MYOD1 TP53 UCHL1

Sources for Malignant Mesenchymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....